[ad_1] HERZLIYA, Israel and CALGARY, AB, Nov. 27, 2025 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan“), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, […]

[ad_1] Two goats suffering from chronic and disabling painful condition were treated with subcutaneous Synthetic Liposomal Cannabidiol (LPT-CBD, 5 mg/kg) injections every six weeks for 10 months. Throughout the study, serial blood sampling was performed […]

[ad_1] HERZLIYA, Israel and CALGARY, AB, Oct. 24, 2025 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to […]

[ad_1] Innovative Chronic Pain Treatment Receives allowance for IP Protection in Japan’s World Third Largest Pharmaceutical Market HERZLIYA, Israel and CALGARY, AB, Oct. 15, 2025 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) […]

[ad_1] This is the second successful treatment in a donkey, demonstrating the potential of Innocan’s Liposomal CBD injection for human and veterinary use HERZLIYA, Israel and CALGARY, AB, Feb. 10, 2025 /PRNewswire/ — Innocan Pharma Corporation […]